LIF 313Alternative Names: LI 313
Latest Information Update: 08 Jun 2010
At a glance
- Originator Enhance Lifesciences
- Mechanism of Action Signal transduction pathway inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Psoriasis
Most Recent Events
- 18 May 2006 Development discontinued for Psoriasis during 2006
- 03 Nov 2003 Phase-I clinical trials in Psoriasis in USA (Topical)